Rationale for a randomized, placebo-controlled, Phase 2 study of Rejuveinix (RJX) in COVID-19 patients with acute lung injury and hypoxemic respiratory failure

| Featured


It appears you don’t have a PDF plugin for this browser.
Click here to
download the PDF file.


click on article to view

More Reven News Releases   |   More Research & Development